Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Thursday. The brokerage issued a hold rating on the stock.

Oncternal Therapeutics Price Performance

Oncternal Therapeutics stock opened at $0.53 on Thursday. Oncternal Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.88. The firm has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $0.92. The firm has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.